Glycosaminoglycan sulodexide decreases albuminuria in diabetic patients

Diabetes Research and Clinical Practice

Volumn 38, Issue 1, 1997, Pages 25-31

  Skrha J ^a   Perusicova J ^a   Pont'Uch, P ^b   Oksa A ^c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^c INST OF PREV AND CLINICAL MEDICINE   (Slovakia)

Author keywords

Albuminuria; Diabetes mellitus; Sulodexide

Indexed keywords

ALBUMIN; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; SULODEXIDE; UNCLASSIFIED DRUG; VESSEL DUE F;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG EFFECT; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA;

ADULT; AGED; ALBUMINURIA; ANTILIPEMIC AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; CREATININE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FASTING; FEMALE; GLYCOSAMINOGLYCANS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; SERUM ALBUMIN; TIME FACTORS;

EID: 0342327339     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(97)00076-4     Document Type: Article

References (27)

1. Andersen A.R., Andersen J.K., Christiansen J.S., Deckert T. Prognosis for juvenile diabetics with nephropathy and failing renal function. Acta Med. Scand. 203:1978;131-134.
2. Deckert T., Poulsen J.E., Larsen M. Prognosis of diabetics with diabetes onset before the age of thirty-one. Diabetologia. 14:1978;363-370.
3. Van-Yu Wu., Wilson B., Cohen M.P. Disturbances in glomerular basement membrane glycosaminoglycans in experimental diabetes. Diabetes. 36:1987;679-683.
4. Cohen M.P., Klepser H., Wu V.Y. Undersulphation of glomerular basement membrane heparan sulfate in experimental diabetes and lack of correlation with aldose reductase inhibition. Diabetes. 37:1988;1324-1327.
5. Kverneland A., Feldt-Rasmussen B., Vidal P., Welinder B., Bent-Hansen L., Soegaard U., Deckert T. Evidence of changes in renal charge selectivity in patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 29:1986;634-639.
6. Mogensen C.E. Microalbuminuria, early blood pressure elevation, and diabetic renal disease. Curr. Opin. Endocrinol. Diabetes. 1:1994;239-247.
7. Oshima Y., Isogai S., Mogami K., Ohuchi H., Ohe K. Protective effect of heparin on renal glomerular anionic sites of streptozotocin-injected rats. Diab. Res. Clin. Pract. 25:1994;83-89.
8. Gambaro G., Cavazzana A.O., Luzi P., Piccoli A., Borsatti A., Crepaldi G., Marchi E., Venturini A.P., Baggio B. Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int. 42:1992;285-291.
9. Myrup B., Hansen P.M., Jensen T., Kofoed-Enevoldsen A., Feldt-Rasmussen B., Gram J., Kluft C., Jespersen J., Deckert T. Effect of low-dose heparin on urinary albumin excretion in insulin-dependent diabetes mellitus. Lancet. 345:1995;421-422.
10. Tamsma J.T., van der Woude F.J., Lemkes H.H.P.J. Effect of sulphated glycosaminoglycans on albuminuria in patients with overt diabetic (type 1) nephropathy. Nephrol. Dial. Transplant. 11:1996;182-185.
11. Gambaro G., Baggio B. Glycosaminoglycans: a new paradigm in the prevention of proteinuria and progression of glomerular disease. Nephrol. Dial. Transplant. 11:1996;762-764.
12. Hiebert L.M., Jaques L.B. The observation of heparin on endothelium after injection. Thromb. Res. 8:1986;195-204.
13. Solini A., Carraro A., Barzon I., Crepaldi G. Therapy with glycosaminoglycans lowers albumin excretion rate in non-insulin dependent diabetic patients with microalbuminuria. Diab. Nutr. Metab. 7:1994;304-307.
14. Velussi M., Cernigoi A.M., Dapas F., De Monte A. Glycosaminoglycans oral therapy reduces microalbuminuria, blood fibrinogen levels and limb arteriopathy clinical signs in patients with non-insulin dependent diabetes mellitus. Diab. Nutr. Metab. 9:1996;53-58.
15. 1c by a a new liquid-chromatographic assay:methodology, clinical utility and relation to glucose tolerance evaluated. Clin. Chem. 32:1986;1867-1872.
16. Oturai P.S., Rasch R., Hasselager E., Johansen P.B., Yokoyama H., Thomsen M.K., Myrup B., Kofoed-Enevoldsen A., Deckert T. Effect of heparin and aminoguanidin on glomerular basement membrane thickening in diabetic rats. APMIS. 104:1996;259-264.
17. Kofoed-Enevoldsen A. Heparan sulphate in the pathogenesis of diabetic nephropathy. Diab. Metab. Rev. 11:1995;137-160.
18. Rix D.A., Douglas M.S., Talbot D., Dark J.H., Kirby J.A. Role of glycosaminoglycan (GAGs) in regulation of the immunogenicity of human vascular endothelial cells. Clin. Exp. Immunol. 104:1996;60-65.
19. Tamsma J.T., van den Born J., Bruijn J.A., Assmann K.J.M., Weening J.J., Berden J.H.M., Wieslander J., Schrama E., Hermans J., Veerkamp J.H., Lemkes H.H., van der Woode F.J. Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulphate in the glomerular basement membrane. Diabetologia. 37:1994;313-320.
20. Vernier R.L., Steffes M.W., Sisson-Ross S., Mauer S.M. Heparan sulphate proteoglycan in the glomerular basement membrane in type 1 diabetes mellitus. Kidney Int. 41:1992;1070-1080.
21. Shield J.P.H., Carradus M., Stone J.E., Hunt L.P., Baum J.D., Pennock C.A. Urinary heparan sulphate proteoglycan excretion is abnormal in insulin dependent diabetes. Ann. Clin. Biochem. 32:1995;557-560.
22. Deckert T., Feldt-Rasmussen B., Borch-Johnsen K., Jensen T., Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno Hypothesis. Diabetologia. 32:1988;219-226.
23. Škrha J., Haas T., Šperl M., Stibor V., Štolba P. A six-year follow-up study of the relationship between N-acetyl-β-glucosaminidase and albuminuria in relation to retinopathy. Diabetic Med. 8:1991;817-821.
24. Coffey A.K., Karnovsky M.J. Heparin inhibits mesangial cell proliferation in Habu-venom-induced glomerular injury. Am. J. Pathol. 120:1985;248-255.
25. Vijayagopal P., Ciolino H.P., Radhakrishnamurty B., Berenson G.S. Heparin stimulates proteoglycan synthesis by vascular smooth muscle cells while suppressing cellular proliferation. Atherosclerosis. 94:1992;135-146.
26. Nader H.B., Buonassisi V., Colburn P., Dietrich C.P. Heparin stimulates the synthesis and modifies the sulfation pattern of heparan sulfate proteoglycan from endothelial cells. J. Cell. Physiol. 140:1989;305-310.
27. Gambaro G., Venturini A.P., Noonan D.M., Fries W., Re G., Garbisa S., Milanesi C., Pesarini A., Borsatti A., Marchi E., Baggio B. Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int. 46:1994;797-806.